- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The UK government through the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have advised that vaccination with the AstraZeneca Covid-19 vaccine should continue.
The MHRA reports that following a rigorous scientific review of all the available data, the available evidence does not suggest that blood clots in veins (venous thromboembolism) are caused by the AstraZeneca COVID-19 Vaccine. This follows a detailed review of reported cases as well as data from hospital admissions and GP records. Dr June Raine, MHRA Chief Executive, is quoted as saying "We will continually monitor safety during use of all a vaccines to protect the public, and to ensure the benefits continue to outweigh the risks."
The EMA Pharmacovigilance Risk Assessment Committee (PRAC) confirmed that the benefits of the vaccine continue to outweigh the risk of side effects and the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it. The PRAC advise that "Close safety monitoring of reports of blood clotting disorders will continue, and further studies are being instituted to provide more laboratory data as well as real-world evidence."
Additional data provided by
English
Japanese
